169 related articles for article (PubMed ID: 16432170)
21. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.
Wang G; Weiss C; Sheng P; Bresnick E
Biochem Pharmacol; 1996 May; 51(9):1221-8. PubMed ID: 8645346
[TBL] [Abstract][Full Text] [Related]
22. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL
J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757
[TBL] [Abstract][Full Text] [Related]
23. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
24. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
25. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
[TBL] [Abstract][Full Text] [Related]
26. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
27. Protection of hematopoietic cells against combined O6-benzylguanine and chloroethylnitrosourea treatment by mutant forms of O6-methylguanine DNA methyltransferase.
Williams DA; Maze R; Kurpad C; Pegg A; Erickson LC
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S105-9. PubMed ID: 10933201
[TBL] [Abstract][Full Text] [Related]
28. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
Bowman JE; Reese JS; Lingas KT; Gerson SL
Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
[TBL] [Abstract][Full Text] [Related]
29. SarCNU mediates selection of P140K methylguanine-DNA-methyltransferase transduced human CD34(+) cells in vitro.
Zielske SP; Gerson SL
Blood Cells Mol Dis; 2003; 31(1):48-50. PubMed ID: 12850483
[TBL] [Abstract][Full Text] [Related]
30. [Mutation of human O6-alkylguanine-DNA alkyltransferase confers resistance to O6-benzylguanine].
Wan Y; Wu D; Gao H
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):290-3. PubMed ID: 11778552
[TBL] [Abstract][Full Text] [Related]
31. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
32. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
33. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
Sawai N; Zhou S; Vanin EF; Houghton P; Brent TP; Sorrentino BP
Mol Ther; 2001 Jan; 3(1):78-87. PubMed ID: 11162314
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
35. O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents.
Davis BM; Koç ON; Reese JS; Gerson SL
Prog Exp Tumor Res; 1999; 36():65-81. PubMed ID: 10386065
[No Abstract] [Full Text] [Related]
36. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.
Choi U; DeRavin SS; Yamashita K; Whiting-Theobald N; Linton GF; Loktionova NA; Pegg AE; Malech HL
Exp Hematol; 2004 Aug; 32(8):709-19. PubMed ID: 15308322
[TBL] [Abstract][Full Text] [Related]
37. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Hansen RJ; Nagasubramanian R; Delaney SM; Samson LD; Dolan ME
Carcinogenesis; 2007 May; 28(5):1111-6. PubMed ID: 17116724
[TBL] [Abstract][Full Text] [Related]
38. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
[TBL] [Abstract][Full Text] [Related]
39. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
Gerson SL; Phillips W; Kastan M; Dumenco LL; Donovan C
Blood; 1996 Sep; 88(5):1649-55. PubMed ID: 8781420
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
